Applies to Employer plans.
Covered with requirementsQualification pathways
You can qualify through any one of these.
Adult weight management
All of:
- Patient is new to therapy, new to Prime, or attempting a repeat weight loss course
- Patient is an adult (18 years of age or over)
- Inadequate response to low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to therapy
- Patient is currently on and will continue weight management regimen in combination with the requested agent
- Patient will NOT use requested agent in combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
- Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
- Patient does NOT have any FDA labeled contraindications
- ONE of the Zepbound continuation criteria met: starting therapy, less than 52 weeks of therapy, or achieved and maintained ≥ 5% weight loss from baseline
Plus any one of:
- Pretreatment BMI ≥ 30 kg/m2
- Pretreatment BMI ≥ 25 kg/m2 if patient is of South Asian, Southeast Asian, or East Asian descent
- Pretreatment BMI ≥ 27 kg/m2 with at least one weight-related comorbidity/risk factor/complication (e.g., hypertension, T2DM, OSA, CVD, dyslipidemia)
Pediatric weight management (12-17 years)
All of:
- Patient is new to therapy, new to Prime, or attempting a repeat weight loss course
- Patient is pediatric (12 to 17 years of age)
- Inadequate response to low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to therapy
- Patient is currently on and will continue weight management regimen in combination with the requested agent
- Patient will NOT use requested agent in combination with another weight loss agent
- Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
- Patient does NOT have any FDA labeled contraindications
- ONE of the Zepbound continuation criteria met: starting therapy, less than 52 weeks of therapy, or achieved and maintained ≥ 5% weight loss from baseline
Plus any one of:
- Pretreatment BMI ≥ 95th percentile for age and sex
- Pretreatment BMI ≥ 30 kg/m2
- Pretreatment BMI ≥ 85th percentile for age and sex AND at least one weight-related comorbidity/risk factor/complication (e.g., hypertension, dyslipidemia, T2DM, OSA)
Another FDA labeled indication (weight management pathway override)
All of:
- Patient has another FDA labeled indication for the requested agent and route of administration
- Patient will NOT use requested agent in combination with another weight loss agent
- Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
- Patient does NOT have any FDA labeled contraindications
- Patient is currently on and will continue weight management regimen
Documentation to bring
- Baseline BMI documentation
- Documentation of at least 6 months of inadequate response to low-calorie diet, increased physical activity, and behavioral modifications (for initial approval)
- Documentation that patient is currently on weight management regimen (diet, physical activity, behavioral modifications)
- For Asian descent patients: documentation of ethnicity supporting lower BMI threshold
- For patients with comorbidities qualifying at BMI ≥ 27: documentation of qualifying comorbidity
- For pediatric patients: documentation of BMI percentile for age and sex
- Confirmation that patient will not combine with another weight loss agent or GLP-1 RA
- For continuation: documentation of weight loss ≥ 5% from baseline OR documentation of being within 52 weeks of therapy on maximum-tolerated dose
Quantity limits
- 2.5 MG/0.5ML vial — 2 mL per 180-day supply (84-day)
- 5 MG/0.5ML vial — 2 mL per 28-day supply
- 7.5 MG/0.5ML vial, 10 MG/0.5ML vial, 12.5 MG/0.5ML vial, 15 MG/0.5ML vial — 4 vials per 28-day supply
- 2.5 MG/0.5ML autoinjector — 4 pens per 180-day supply (84-day)
- 5 MG/0.5ML autoinjector, 7.5 MG/0.5ML autoinjector, 10 MG/0.5ML autoinjector, 12.5 MG/0.5ML autoinjector, 15 MG/0.5ML autoinjector — 4 pens per 28-day supply
- 2.5 MG/0.6ML kwikpen — 1 pen per 180-day supply (84-day)
- 5 MG/0.6ML kwikpen, 7.5 MG/0.6ML kwikpen, 10 MG/0.6ML kwikpen, 12.5 MG/0.6ML kwikpen, 15 MG/0.6ML kwikpen — 1 pen per 28-day supply
Approval and renewal
- Initial approval: 12 months
- Renewal: every 12 months
- Renewal: For renewal (weight management): patient must have received less than 52 weeks of therapy on the maximum-tolerated dose OR achieved and maintained ≥ 5% weight loss from baseline. Pediatric patients must also maintain BMI ≥ 85th percentile at renewal. Initial BMI thresholds and 6-month lifestyle program pre-therapy requirement are not explicitly re-verified at renewal.
Not covered when
- Combination use with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
- Combination use with another GLP-1 receptor agonist
- Any FDA labeled contraindications to the requested agent
Exceptions
- BCBS_NM_Fully_Insured_or_HIM: May be approved if patient does not have FDA labeled contraindications AND the requested indication is a rare disease AND patient has another FDA labeled indication or compendia-supported indication.
- Ohio_Fully_Insured_or_HIM_SHOP: May be approved if member resides in Ohio, plan is Fully Insured or HIM Shop (SG), no FDA labeled contraindications, AND patient has another FDA labeled or compendia-supported indication OR prescriber submits two articles from major peer-reviewed journals.
Policy note: Approval duration for BCBS IL HIM/FI/ASO Cost (BBF) and BCBSMT FI & HIM is 12 months. For all other plans: initial and renewal approval is 12 months. Zepbound includes vial, autoinjector (soln autoinjector), and kwikpen (soln pen-injector) formulations. Note Zepbound is also covered under a separate OSA indication with different criteria.
Policy effective May 18, 2026 · verified June 2, 2026 · source: Hcsc Weight Management Prog Sum · View policy document (PDF)